Among the Lp(a) research highlights, presented at the American Heart Association Scientific Sessions 2025 (7-10 November, New Orleans), were a further analysis of data from the Phase 2 OCEAN(a)-DOSE study and new insights into the role of Lp(a) in myocardial inflammation, opportunities to address barriers to Lp(a) clinical trial recruitment, projections on the impact of Lp(a) lowering on coronary heart disease risk, and the potential impact of social deprivation on epigenetic modification of the LPA gene and changes in plasma Lp(a) levels.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
